LY2183240
| Title | Journal |
|---|---|
| The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH). | Bioorganic & medicinal chemistry letters 20110815 |
| Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference. | Psychopharmacology 20101201 |
| Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. | Journal of medicinal chemistry 20091210 |
| Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors. | Journal of medicinal chemistry 20091126 |
| Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. | Journal of medicinal chemistry 20090108 |
| The endocannabinoid anandamide inhibits kinin B1 receptor sensitization through cannabinoid CB1 receptor stimulation in human umbilical vein. | European journal of pharmacology 20090105 |
| Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. | Journal of medicinal chemistry 20081211 |
| Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation. | European journal of medicinal chemistry 20080101 |
| The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. | Journal of the American Chemical Society 20060802 |